This site is intended for health professionals only

Sanofi completes Zentiva takeover

teaser

Paris-based Sanofi-Aventis has completed its takeover of Czech pharmaceutical company Zentiva in a deal that makes it the world’s 11th-largest generic-drugs manufacturer.

It now owns 94% of Zentiva, which makes and sells generic drugs in Central and Eastern Europe, including products for pain, cardiovascular diseases and central nervous system disorders.

Sanofi’s initial takeover bid of 1.65 billion euros (£1.48 billion) last June was rejected by Zentiva’s management in July. A revised offer of 1.8 billion euros (£1.6 billion) in September was accepted.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Sanofi-Aventis began building its stake in Zentiva more than two years ago. It said that shareholders representing 70% of Zentiva’s outstanding capital had tendered their shares in the latest offer.

Copyright Press Association 2009

Sanofi-Aventis






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x